Through our core business – the discovery, development and marketing of innovative treatments – we have helped prevent and treat diseases, ease suffering and improve quality of life for people worldwide.
But as the size and complexity of the world’s healthcare challenges grow, we must widen our scope, extending our impact even further by asking: How can we effectively address the needs of underserved populations? How can we bring the benefits of our medicines to more people? And how can we do this in a way that is sustainable for our business?
It begins with a fundamental shift in the way we do business – with reimagining new ways to bridge the divide between those with access to critical healthcare innovations and those without.
We are committed to bringing more of our medicines to more people, no matter where they are. For all our new medicines, we will systematically integrate access strategies in how we research, develop and deliver globally. This will be a key measure of success for our leaders and employees.